Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Vericel Corp | a13-10501_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 17, 2013
Aastrom Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
Michigan |
|
000-22025 |
|
94-3096597 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
24 Frank Lloyd Wright Drive, P.O. Box |
|
48106 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (734) 418-4400
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On April 17, 2013, Aastrom Biosciences, Inc. (the “Company”) presented at the 1st Annual Regen Med Investor Day in New York, NY. A copy of the presentation, which includes preclinical and clinical data of ixmyelocel-T in patients with dilated cardiomyopathy, is furnished herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Slide presentation dated April 17, 2013. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Aastrom Biosciences, Inc. | |
|
|
| |
|
Date: April 23, 2013 |
By: |
/s/ Dominick C. Colangelo |
|
|
|
Name: Dominick C. Colangelo |
|
|
|
Title: President and Chief Executive Officer |